ONCAlert | AstraZeneca: Pioneers in Ovarian Cancer

Exploring the Combination of Epacadostat and Pembrolizumab in Urothelial Carcinoma

Elizabeth Plimack, MD
Published Online:12:13 PM, Tue August 8, 2017

Elizabeth Plimack, MD, chief of the division of genitourinary medical oncology and director of genitourinary research at Fox Chase Cancer Center in Philadelphia, discusses the combination of epacadostat and pembrolizumab (Keytruda) for the treatment of patients with urothelial carcinoma.
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.